Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
The summary for the Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional): This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this NOFO may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics)and (2) medical therapeutic and diagnostic devices, including software as a medical device. This NOFO strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.
Federal Grant Title: | Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DA-24-038 |
Type of Funding: | Grant |
CFDA Numbers: | 93.279 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | February 14th, 2025 |
Original Application Deadline: | February 14th, 2025 |
Posted Date: | April 18th, 2023 |
Creation Date: | April 18th, 2023 |
Archive Date: | March 22nd, 2025 |
Total Program Funding: | |
Maximum Federal Grant Award: | $300,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | April 18th, 2023 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.
- Link to Full Grant Announcement
- https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-038.html
- Grant Announcement Contact
- NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Tr...
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Tr...
- • NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)
- • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/U...
- • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/U...
- • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...